Nurix therapeutics announces webcast to review new data from its phase 1 clinical trial of btk degrader nx-5948 presented at the 66th american society of hematology (ash) annual meeting

San francisco, dec. 02, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing phase 1a/1b clinical trial of its bruton's tyrosine kinase (btk) degrader program nx-5948, and provide a corporate update, at 8:15 p.m. pt (11:15 p.m. et) on monday, december 9, 2024.
ASH Ratings Summary
ASH Quant Ranking